Medical Center Excelsior OOD
- Address
- lock Available on a paid plan
Medical Center Excelsior OOD - Multi-Specialty Research Center
Medical Center Excelsior OOD is a comprehensive clinical research facility specializing in Phase 2 and Phase 3 trials across multiple therapeutic areas. The center demonstrates particular expertise in autoimmune and inflammatory conditions, with a strong focus on rheumatologic disorders and dermatologic diseases. Their experienced team conducts complex comparative efficacy studies and safety evaluations for novel therapeutic agents.
- Autoimmune diseases including systemic lupus erythematosus, axial spondyloarthritis, and psoriatic arthritis
- Respiratory conditions with emphasis on moderate-to-severe asthma and T2-high asthma phenotypes
- Dermatologic disorders, particularly atopic dermatitis and combination therapy trials
- Metabolic and inflammatory conditions including gout with hyperuricemia
The facility has established capabilities in conducting observer-blind and placebo-controlled trials, managing complex dosing regimens, and evaluating both biologic and small molecule therapies. Their research portfolio includes innovative treatment approaches ranging from targeted JAK inhibitors to novel immunomodulatory agents, as well as vaccine efficacy studies in elderly populations. The center's infrastructure supports comprehensive assessment of disease activity biomarkers, immunogenicity testing, and long-term safety monitoring across diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 11 therapeutic areas and 15 of 80 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 78 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1Novo Nordisk A/S2active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.4trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Excelsior OOD
lock Showing 1 of 55 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 80 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238) | 3 | Unknown | 2023-10-20 | 2025-10-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.